Pharmacy

Top Medical News
“Inclisiran first” strategy yields greater LDL-C reduction in ASCVD patients
Elaine Soliven, 3 hours ago

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Web-based app to guide nonprescription use of statins a win in TACTiC trial
Jairia Dela Cruz, 13 hours ago
Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.
Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis
21 hours ago
In the treatment of radiographic axial spondyloarthritis (r-axSpA), the 2-year incidence of spinal radiographic progression is low and not different between secukinumab and adalimumab biosimilar, as shown in the phase IIIb study SURPASS study.
AXS-07 effective migraine treatment in pooled phase III analysis
Elaine Soliven, Yesterday

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

SGLT2 inhibitors a promising gout medication in T2D
Jairia Dela Cruz, Yesterday
The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.
Erenumab helps with rosacea-associated flushing, erythema
Yesterday
Monthly subcutaneous injections of the anti–CGRP-receptor monoclonal antibody erenumab appear to be beneficial in the management of flushing and chronic redness among individuals with rosacea, according to a study.
Supplementation with essential amino acid improves liver health in teen girls with PCOS
Rachel Tang, 2 days ago
Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among adolescent girls with polycystic ovarian syndrome (PCOS) in a recent study.
Special Reports
Product Highlight - MENQUADFI
13 Apr 2024
Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection
Product Highlight - LYPSTAPLUS
11 Apr 2024
Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet
Nirmatrelvir reduces the risk of long COVID
05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.1

Nicorette® QuickMist Launch Symposium
19 Jan 2024
During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Navigating invasive fungal infections in unconventional hosts — insights and strategies
Assoc Prof. Carolina García-Vidal, Dr. Jasmine Chung, 06 Jan 2024

At a recent symposium organized by Pfizer, in collaboration with the Society of Infectious Disease Singapore, A/Prof Carolina García-Vidal, Senior Specialist, Infectious Diseases Department at Hospital Clínic de Barcelona, Spain, shared valuable insights on managing invasive fungal infections (IFIs) in nontraditional hosts. The session was chaired by Dr Jasmine Chung, Senior Consultant and Director of the Antimicrobial Stewardship Unit, Singapore General Hospital.

Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore
06 Dec 2023
In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.
Conference Reports
“Inclisiran first” strategy yields greater LDL-C reduction in ASCVD patients
Elaine Soliven, 25 Apr 2024

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Web-based app to guide nonprescription use of statins a win in TACTiC trial
Jairia Dela Cruz, 24 Apr 2024
Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.
AXS-07 effective migraine treatment in pooled phase III analysis
Elaine Soliven, 24 Apr 2024

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
Jairia Dela Cruz, 19 Apr 2024
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.
Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia
Elaine Soliven, 19 Apr 2024

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Injectable atezolizumab favoured over intravenous infusion
Jairia Dela Cruz, 18 Apr 2024
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
Amivantamab plus chemo tied to better outcomes in NSCLC
Stephen Padilla, 17 Apr 2024
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.